Rheumatoid arthritis, other autoimmune disorders

Guidelines (21)

Certolizumab Pegol and Secukinumab for Treating Active Psoriatic Arthritis after Inadequate Response to DMARDS (TA445)

24 May 2017

Apremilast for Treating Active Psoriatic Arthritis (TA433)

22 February 2017

Certolizumab Pegol for Treating Rheumatoid Arthritis after Inadequate Response to a TNF-Alpha Inhibitor (TA415)

26 October 2016

Secukinumab for Active Ankylosing Spondylitis after Treatment with Non-Steroidal Anti-Inflammatory Drugs or TNF-Alpha Inhibitors (TA407)

28 September 2016

Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus (TA397)

22 June 2016

TNF-Alpha Inhibitors for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis (TA383)

2 February 2016

Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab, Tocilizumab and Abatacept for Rheumatoid Arthritis Not Previously Treated with DMARDs or after Conventional DMARDs Only Have Failed (TA375)

26 January 2016

Abatacept, Adalimumab, Etanercept and Tocilizumab for Treating Juvenile Idiopathic Arthritis (TA373)

16 December 2015

Ustekinumab for Treating Active Psoriatic Arthritis (TA340 [rapid review of TA313])

8 June 2015

Rituximab in Combination with Glucocorticoids for Treating Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (TA308)

26 March 2014

Load More
Tables (1)

Table: DMARDs, a Guide to Monitoring Requirements

18 July 2018

Tests for patients on disease-modifying arthritis drugs.

Rheumatoid arthritis, other autoimmune disorders in the News

DMARDs, a Guide to Monitoring Requirements

DMARDs, a Guide to Monitoring Requirements

18 July 2018

Tests for patients on disease-modifying arthritis drugs.

Arthritis biologic approved for NHS prescribing

Arthritis biologic approved for NHS prescribing

By Chloe Harman, 3 November 2017

Sarilumab (Kevzara) is to be funded on the NHS, following...

Tofacitinib approved by NICE for severe rheumatoid arthritis

Tofacitinib approved by NICE for severe rheumatoid arthritis

By Sandhiya Sodha, 12 October 2017

The JAK inhibitor tofacitinib (Xeljanz) has been endorsed...

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Twitter